
Novel ADC Shows Promise of Targeting CD46 in mCRPC
FOR46 (FG-3246), an immune-modulating antibody-drug conjugate targeting CD46, had a manageable safety profile and elicited promising preliminary activity in patients with metastatic castration-resistant prostate cancer (mCRPC), according to findings from a …